China Resources Pharmaceutical Group Ltd.（3320.HK）股价、财务与研究

盘中时间采用HKT。市场数据可能有所延迟。

公司概况

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

行业: Medical - Pharmaceuticals
部门: Healthcare
总部: HK
首席执行官: Xiaosong Bai
上市以来: 2016年10月28日
雇员: 85,600

市场位置

52周区间

当前HK$4.705，

HK$4.22HK$6.53

开盘价: HK$4.705
前收盘价: HK$4.81
成交量: 1105.47万; 1.06× 平均值
平均成交量: 1041.36万; 日均成交量
市值: 295.59亿 HKD
贝塔: -0.39; 市场参考 1
50天平均值: HK$4.6951; 高于平均水平+0.21%
200天平均值: HK$4.8574; 低于平均水平-3.14%

财务数据

财务快照

估值与收益率

市盈率（TTM）: 6.63×
市净率（TTM）: 0.52×
市销率（TTM）: 0.1×
股息率: 4.63%

盈利能力和效率

毛利率: 16.51%
营业利润率: 4.63%
净利润率: 1.50%

财务健康

负债权益比: 1.83×

财务报表

利润率趋势

盈利能力占已公布营收的百分比。

毛利率营业利润率净利润率

损益趋势

营收

3000.13亿 HKD+9.42%

营业利润

139.02亿 HKD+10.67%

净利润

45.02亿 HKD+26.27%

项目（HKD）	2025财年	2024财年	2023财年	2022财年	2021财年
营收	3000.13亿 HKD	2741.82亿 HKD	2703.97亿 HKD	2231.3亿 HKD	1932.36亿 HKD
销货成本	2504.8亿 HKD	2308.87亿 HKD	2284.07亿 HKD	1887.66亿 HKD	1643.66亿 HKD
毛利	495.33亿 HKD	432.96亿 HKD	424.32亿 HKD	343.64亿 HKD	288.71亿 HKD
研究与开发	31.54亿 HKD	24.75亿 HKD	27.29亿 HKD	18.35亿 HKD	13.78亿 HKD
销售、一般及管理费用	324.77亿 HKD	282.59亿 HKD	277.91亿 HKD	192.95亿 HKD	158.53亿 HKD
营业费用	356.31亿 HKD	307.32亿 HKD	305.2亿 HKD	248.7亿 HKD	213.24亿 HKD
利息收入	5.25亿 HKD	6.81亿 HKD	5.88亿 HKD	7.32亿 HKD	5.95亿 HKD
利息支出	21.98亿 HKD	22.82亿 HKD	23.86亿 HKD	25.06亿 HKD	22.12亿 HKD
折旧和摊销	36.22亿 HKD	27.01亿 HKD	31.64亿 HKD	27.68亿 HKD	23.03亿 HKD
营业利润	139.02亿 HKD	125.62亿 HKD	139.01亿 HKD	94.94亿 HKD	75.47亿 HKD
净利润	45.02亿 HKD	35.66亿 HKD	42.4亿 HKD	36.42亿 HKD	30.75亿 HKD